| 18.60 Delayed Data As of Oct 12 |  0.00 / 0.00%Today’s Change | 16.96 Today|||52-Week Range 21.30 | +5.68% Year-to-Date |
| Pharma Stock Roundup: ABBV, NVS' Humira Biosimilar Agreement, BMY's New Cancer Deal Oct 12 / Zacks.com - Paid Partner Content | J&J's Phase III Data Shows Switch to its HIV Drug Beneficial Oct 04 / Zacks.com - Paid Partner Content |
| Novartis Presents Positive Data on Sickle Cell Disease Drug Oct 10 / Zacks.com - Paid Partner Content | Gilead, HiFiBiO Collaborate to Develop T-Cell Receptors Oct 03 / Zacks.com - Paid Partner Content |
| Merck Reports Positive Efficacy Data from Phase III HIV Study Oct 05 / Zacks.com - Paid Partner Content | Why Dynavax Technologies Corporation Stock Struggled in September Oct 03 / MotleyFool.com - Paid Partner Content |
| Gilead Announces Positive Data From Ongoing Biktarvy Study Oct 05 / Zacks.com - Paid Partner Content |
| Previous close | 18.60 |
| Today’s open | 19.37 |
| Day’s range | 18.60 - 19.37 |
| Volume | 2,823 |
| Average volume (3 months) | 2,838 |
| Market cap | $92.3B |
| Earnings growth (last year) | +59.40% |
| Earnings growth (this year) | -- |
| Earnings growth (next 5 years) | -- |
| Revenue growth (last year) | +3.30% |
| P/E ratio | 12.3 |
| Price/Sales | 2.27 |
| Price/Book | -- |
| No competitors data available. |
| Next reporting date | -- |
| EPS forecast (this quarter) | -- |
| Annual revenue (last year) | $38.9B |
| Annual profit (last year) | $2.0B |
| Net profit margin | 5.08% |
Sector Health Technology |
Industry Pharmaceuticals: Major |
Chief Executive Officer & Executive Director Emma Walmsley |
Chief Financial Officer & Executive Director Simon Paul Dingemans |
Corporate headquarters Brentford, Greater London |
